Actively Recruiting
Evaluation of 68Ga-P3 PETCT Imaging Targeting PSMA in Adults with Confirmed or Suspected Cancer
Led by Peking University First Hospital · Updated on 2024-11-07
350
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the use of 68Ga-P3 PETCT imaging to detect prostate-specific membrane antigen PSMA expression in malignant tumors. PSMA is a protein found in high amounts on prostate cancer cells and blood vessels of tumors, making it an important target for imaging various cancers. This study aims to assess how well 68Ga-P3, a new PET imaging agent, works for diagnosing cancers that highly express PSMA. Participants with suspected or confirmed cancer will receive an intravenous injection of 68Ga-P3 at a dose of 0.06 to 0.08 mCikg. After the injection, PET imaging using 68Ga-P3 will be performed. Additionally, participants will undergo a whole-body 18F-FDG PETCT scan within one week for comparison. This interventional study focuses on gathering diagnostic and detection information about malignant tumors. During the study, researchers will measure the diagnostic accuracy and detection capabilities of 68Ga-P3 PETCT over one year. They will also evaluate the radiation dosage from 68Ga-P3, quantify its uptake, and correlate imaging results with pathological findings. Participants will be monitored through scans and tests as part of the imaging procedures, and the study will last for one year to collect these outcomes.
CONDITIONS
Brief Title
68Ga-P3 PET/CT Imaging in Malignancy
Research Team
X
Xing Yang, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
